RU2018146264A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018146264A3 RU2018146264A3 RU2018146264A RU2018146264A RU2018146264A3 RU 2018146264 A3 RU2018146264 A3 RU 2018146264A3 RU 2018146264 A RU2018146264 A RU 2018146264A RU 2018146264 A RU2018146264 A RU 2018146264A RU 2018146264 A3 RU2018146264 A3 RU 2018146264A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610410554 | 2016-06-13 | ||
| CN201610410554.8 | 2016-06-13 | ||
| PCT/CN2017/087546 WO2017215506A1 (zh) | 2016-06-13 | 2017-06-08 | 作为TGF-βR1抑制剂的苯并三氮唑衍生的α，β不饱和酰胺类化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018146264A3 true RU2018146264A3 (ru) | 2020-07-15 |
| RU2018146264A RU2018146264A (ru) | 2020-07-15 |
| RU2737737C2 RU2737737C2 (ru) | 2020-12-02 |
Family
ID=60664287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018146264A RU2737737C2 (ru) | 2016-06-13 | 2017-06-08 | АЛЬФА- И БЕТА-НЕНАСЫЩЕННОЕ АМИДНОЕ СОЕДИНЕНИЕ - ПРОИЗВОДНОЕ БЕНЗОТРИАЗОЛА, ПРИМЕНЯЕМОЕ В КАЧЕСТВЕ ИНГИБИТОРА TGF-βRI |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10548883B2 (ru) |
| EP (1) | EP3470409B1 (ru) |
| JP (1) | JP6954932B2 (ru) |
| KR (1) | KR102412035B1 (ru) |
| CN (1) | CN109415341B (ru) |
| AU (1) | AU2017284124B2 (ru) |
| BR (1) | BR112018075736B1 (ru) |
| CA (1) | CA3027425C (ru) |
| DK (1) | DK3470409T3 (ru) |
| ES (1) | ES2787449T3 (ru) |
| PT (1) | PT3470409T (ru) |
| RU (1) | RU2737737C2 (ru) |
| WO (1) | WO2017215506A1 (ru) |
| ZA (1) | ZA201808618B (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11236112B2 (en) | 2017-12-13 | 2022-02-01 | Genfleet Therapeutics (Shanghai) Inc. | Crystal form and salt form of TGF-βRI inhibitor and preparation method therefor |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3840748A4 (en) | 2018-08-22 | 2022-06-29 | Clavius Pharmaceuticals, LLC | Substituted imidazoles for the inhibition of tgf-beta and methods of treatment |
| WO2020088526A1 (zh) * | 2018-10-31 | 2020-05-07 | 南京明德新药研发有限公司 | 作为TGF-βR1激酶抑制剂的双环吡唑类化合物 |
| EP3956330A4 (en) | 2019-04-18 | 2023-01-18 | The Johns Hopkins University | SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE |
| CN112694477B (zh) * | 2019-10-22 | 2024-02-06 | 四川科伦博泰生物医药股份有限公司 | 吡唑并环类化合物，包含其的药物组合物，其制备方法及其用途 |
| WO2021136431A1 (zh) * | 2019-12-31 | 2021-07-08 | 南京明德新药研发有限公司 | 苯并[d][1,2,3]三唑醚类化合物 |
| WO2021190425A1 (zh) * | 2020-03-24 | 2021-09-30 | 杭州阿诺生物医药科技有限公司 | 转化生长因子-β受体抑制剂 |
| CN113698395B (zh) * | 2020-05-22 | 2023-12-08 | 赛诺哈勃药业（成都）有限公司 | 转化生长因子受体拮抗剂、其制备方法和应用 |
| CN112851695A (zh) * | 2021-01-27 | 2021-05-28 | 复旦大学附属华山医院 | 甲酰胺类化合物在制备抗脊索肿瘤药物中的应用及试剂盒 |
| CN115969801B (zh) * | 2023-03-21 | 2023-08-25 | 劲方医药科技(上海)有限公司 | 用于癌症的药物组合物及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1951939A (zh) | 2001-05-24 | 2007-04-25 | 伊莱利利公司 | 作为药物的新的吡唑衍生物 |
| BR0314302A (pt) * | 2002-09-18 | 2005-07-05 | Pfizer Producs Inc | Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf) |
| US7405299B2 (en) * | 2002-11-27 | 2008-07-29 | Eli Lilly And Company | Compounds as pharmaceutical agents |
| CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| CA2578628A1 (en) * | 2004-08-31 | 2006-03-09 | Biogen Idec Ma Inc. | Pyrimidinylpyrazoles as tgf-beta inhibitors |
| WO2007076127A2 (en) | 2005-12-22 | 2007-07-05 | Biogen Idec Ma Inc | Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators |
| WO2009009059A1 (en) | 2007-07-09 | 2009-01-15 | Biogen Idec Ma Inc. | Spiro compounds as antagonists of tgf-beta |
| US8080568B1 (en) * | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
-
2017
- 2017-06-08 WO PCT/CN2017/087546 patent/WO2017215506A1/zh unknown
- 2017-06-08 AU AU2017284124A patent/AU2017284124B2/en active Active
- 2017-06-08 DK DK17812617.3T patent/DK3470409T3/da active
- 2017-06-08 CN CN201780036957.3A patent/CN109415341B/zh active Active
- 2017-06-08 CA CA3027425A patent/CA3027425C/en active Active
- 2017-06-08 BR BR112018075736-5A patent/BR112018075736B1/pt active IP Right Grant
- 2017-06-08 JP JP2018566420A patent/JP6954932B2/ja active Active
- 2017-06-08 KR KR1020197001025A patent/KR102412035B1/ko active IP Right Grant
- 2017-06-08 US US16/308,859 patent/US10548883B2/en active Active
- 2017-06-08 RU RU2018146264A patent/RU2737737C2/ru active
- 2017-06-08 PT PT178126173T patent/PT3470409T/pt unknown
- 2017-06-08 EP EP17812617.3A patent/EP3470409B1/en active Active
- 2017-06-08 ES ES17812617T patent/ES2787449T3/es active Active
-
2018
- 2018-12-20 ZA ZA2018/08618A patent/ZA201808618B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11236112B2 (en) | 2017-12-13 | 2022-02-01 | Genfleet Therapeutics (Shanghai) Inc. | Crystal form and salt form of TGF-βRI inhibitor and preparation method therefor |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102412035B1 (ko) | 2022-06-22 |
| CN109415341B (zh) | 2021-02-26 |
| RU2737737C2 (ru) | 2020-12-02 |
| AU2017284124A1 (en) | 2019-01-24 |
| EP3470409A4 (en) | 2019-05-08 |
| WO2017215506A1 (zh) | 2017-12-21 |
| PT3470409T (pt) | 2020-05-11 |
| CA3027425C (en) | 2023-08-15 |
| US10548883B2 (en) | 2020-02-04 |
| JP2019518066A (ja) | 2019-06-27 |
| EP3470409A1 (en) | 2019-04-17 |
| JP6954932B2 (ja) | 2021-10-27 |
| DK3470409T3 (da) | 2020-05-11 |
| BR112018075736A2 (pt) | 2019-03-26 |
| US20190151299A1 (en) | 2019-05-23 |
| AU2017284124B2 (en) | 2021-06-03 |
| CN109415341A (zh) | 2019-03-01 |
| BR112018075736B1 (pt) | 2024-01-23 |
| ZA201808618B (en) | 2019-08-28 |
| ES2787449T3 (es) | 2020-10-16 |
| RU2018146264A (ru) | 2020-07-15 |
| KR20190017959A (ko) | 2019-02-20 |
| EP3470409B1 (en) | 2020-02-12 |
| CA3027425A1 (en) | 2017-12-21 |